Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-03-08 13:57:48 UTC |
---|
Update Date | 2023-02-21 17:15:56 UTC |
---|
HMDB ID | HMDB0001895 |
---|
Secondary Accession Numbers | - HMDB0015470
- HMDB01895
- HMDB15470
|
---|
Metabolite Identification |
---|
Common Name | Salicylic acid |
---|
Description | Salicylic acid is a monohydroxybenzoic acid that is benzoic acid with a hydroxy group at the ortho position. It is obtained from the bark of the white willow and wintergreen leaves. It has a role as an antiinfective agent, an antifungal agent, a keratolytic drug, an EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor, a plant metabolite, an algal metabolite and a plant hormone. It is a conjugate acid of a salicylate. It is a colorless solid, it is a precursor to and a metabolite of aspirin (acetylsalicylic acid). It is a plant hormone. The name is from Latin salix for willow tree. It is an ingredient in some anti-acne products. Salts and esters of salicylic acid are known as salicylates. Salicylic acid modulates COX1 enzymatic activity to decrease the formation of pro-inflammatory prostaglandins. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (UDPG) competitively with nicotinamide adenosine dinucleotide and noncompetitively with UDPG. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis. Salicylic acid is biosynthesized from the amino acid phenylalanine. In Arabidopsis thaliana, it can be synthesized via a phenylalanine-independent pathway. |
---|
Structure | InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10) |
---|
Synonyms | Value | Source |
---|
2-Carboxyphenol | ChEBI | 2-HYDROXYBENZOIC ACID | ChEBI | O-Carboxyphenol | ChEBI | O-Hydroxybenzoic acid | ChEBI | 2-HYDROXYBENZOate | Generator | O-Hydroxybenzoate | Generator | Salicylate | Generator | 2 Hydroxybenzoic acid | MeSH | Acid, 2-hydroxybenzoic | MeSH | Acid, salicylic | MeSH | Acid, O-hydroxybenzoic | MeSH | Acid, ortho-hydroxybenzoic | MeSH | O Hydroxybenzoic acid | MeSH | Ortho hydroxybenzoic acid | MeSH | Ortho-hydroxybenzoic acid | MeSH | 2-Hydroxybenzenecarboxylate | HMDB | 2-Hydroxybenzenecarboxylic acid | HMDB | Advanced pain relief callus removers | HMDB | Advanced pain relief corn removers | HMDB | Clear away wart remover | HMDB | Compound W | HMDB | Dr. scholl's callus removers | HMDB | Dr. scholl's corn removers | HMDB | Dr. scholl's wart remover kit | HMDB | Duofil wart remover | HMDB | Duoplant | HMDB | Freezone | HMDB | Ionil | HMDB | Ionil plus | HMDB | K 537 | HMDB | K 557 | HMDB | Phenol-2-carboxylate | HMDB | Phenol-2-carboxylic acid | HMDB | Psoriacid-S-stift | HMDB | Retarder W | HMDB | Rutranex | HMDB | Salicylic acid collodion | HMDB | Salicylic acid soap | HMDB | Saligel | HMDB | Salonil | HMDB | Stri-dex | HMDB | trans-Ver-sal | HMDB | SA | PhytoBank |
|
---|
Chemical Formula | C7H6O3 |
---|
Average Molecular Weight | 138.122 |
---|
Monoisotopic Molecular Weight | 138.031694053 |
---|
IUPAC Name | 2-hydroxybenzoic acid |
---|
Traditional Name | salicylic |
---|
CAS Registry Number | 69-72-7 |
---|
SMILES | OC(=O)C1=C(O)C=CC=C1 |
---|
InChI Identifier | InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10) |
---|
InChI Key | YGSDEFSMJLZEOE-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Benzoic acids and derivatives |
---|
Direct Parent | Salicylic acids |
---|
Alternative Parents | |
---|
Substituents | - Salicylic acid
- Benzoic acid
- Benzoyl
- 1-hydroxy-4-unsubstituted benzenoid
- 1-hydroxy-2-unsubstituted benzenoid
- Phenol
- Vinylogous acid
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | Not Available |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 158 °C | Not Available | Boiling Point | 211.00 °C. @ 20.00 mm Hg | The Good Scents Company Information System | Water Solubility | 2.24 mg/mL at 25 °C | Not Available | LogP | 2.26 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Salicylic acid,1TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC=CC=C1O | 1373.2 | Semi standard non polar | 33892256 | Salicylic acid,1TMS,isomer #2 | C[Si](C)(C)OC1=CC=CC=C1C(=O)O | 1491.3 | Semi standard non polar | 33892256 | Salicylic acid,2TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CC=CC=C1O[Si](C)(C)C | 1524.4 | Semi standard non polar | 33892256 | Salicylic acid,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC=CC=C1O | 1612.5 | Semi standard non polar | 33892256 | Salicylic acid,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC=CC=C1C(=O)O | 1751.7 | Semi standard non polar | 33892256 | Salicylic acid,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CC=CC=C1O[Si](C)(C)C(C)(C)C | 1970.3 | Semi standard non polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Salicylic acid GC-MS (2 TMS) | splash10-014i-3890000000-62eae168a9d7ab3ada6f | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Salicylic acid EI-B (Non-derivatized) | splash10-00du-9700000000-e1e2ee6b61d86c596403 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Salicylic acid GC-MS (Non-derivatized) | splash10-014i-3890000000-62eae168a9d7ab3ada6f | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Salicylic acid GC-EI-TOF (Non-derivatized) | splash10-014i-2960000000-1b6b46cbb2b643b71448 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylic acid GC-MS (Non-derivatized) - 70eV, Positive | splash10-0079-8900000000-e8ee46d81fcc1ce3766e | 2016-09-22 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylic acid GC-MS (2 TMS) - 70eV, Positive | splash10-006x-8950000000-9ed3a56f2b2654ba281f | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylic acid GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Salicylic acid GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-00du-9600000000-6d4a0ff2d48d814b5c54 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid Quattro_QQQ 10V, Negative-QTOF (Annotated) | splash10-059j-9600000000-54545731fceee84be340 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid Quattro_QQQ 25V, Negative-QTOF (Annotated) | splash10-00xu-9500000000-2f1c989b672669aaf083 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid Quattro_QQQ 40V, Negative-QTOF (Annotated) | splash10-0gb9-9000000000-a0049e982e8ecd7ab730 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negative-QTOF | splash10-000i-0900000000-f1e71df6894bcc8dda74 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negative-QTOF | splash10-0006-9200000000-f9fd317c182ec7ca90dc | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negative-QTOF | splash10-0006-9000000000-2b17aea4ee0ddd6321cf | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negative-QTOF | splash10-0006-9000000000-320b7cd879b61439cf42 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negative-QTOF | splash10-0006-9000000000-7d1b96d60026076a7ecc | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid ESI-TOF , Negative-QTOF | splash10-002b-0496100000-97708001d2a6d031beff | 2017-08-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid ESI-TOF 10V, Negative-QTOF | splash10-002b-0496100000-97708001d2a6d031beff | 2017-08-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid ESI-TOF , Negative-QTOF | splash10-002b-0496100000-97708001d2a6d031beff | 2017-09-12 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid ESI-TOF 10V, Negative-QTOF | splash10-000i-0900000000-f88c693bac9b89416a52 | 2017-09-12 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QFT , negative-QTOF | splash10-0006-9400000000-b0fb5458dfa73429b976 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QFT , negative-QTOF | splash10-0006-9400000000-b0fb5458dfa73429b976 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QFT , negative-QTOF | splash10-0006-9100000000-237ee14e8af5262c0dab | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QFT , negative-QTOF | splash10-0006-9000000000-3ec5d7a9114e37b8af2a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QFT , negative-QTOF | splash10-0006-9000000000-d8fdab29114453b10280 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QFT , negative-QTOF | splash10-0006-9000000000-4a337e3639c9f42a9000 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QFT , negative-QTOF | splash10-0006-9000000000-2deb0e843e099fdcea99 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QFT , negative-QTOF | splash10-00kf-9000000000-951b374b351c5534628a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QFT , negative-QTOF | splash10-014l-9000000000-4ea52d5aa4344a40c007 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QQ , negative-QTOF | splash10-000i-0900000000-f1e71df6894bcc8dda74 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QQ , negative-QTOF | splash10-0006-9200000000-65f3f297188dc07b53be | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QQ , negative-QTOF | splash10-0006-9000000000-2b17aea4ee0ddd6321cf | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Salicylic acid LC-ESI-QQ , negative-QTOF | splash10-0006-9000000000-320b7cd879b61439cf42 | 2017-09-14 | HMDB team, MONA | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | Not Available |
---|
Biospecimen Locations | |
---|
Tissue Locations | |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Consuming polyphenols described by Phenol-Explorer entry 428 | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.020-0.200 uM | Adult (>18 years old) | Male | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Feces | Detected and Quantified | 1.303 +/- 0.145 nmol/g wet feces | Adult (>18 years old) | Both | Normal | | details | Feces | Detected and Quantified | 2.751 +/- 3.0408 nmol/g wet feces | Adult (>18 years old) | Both | Normal | | details | Feces | Detected and Quantified | 4.996 +/- 9.557 nmol/g wet feces | Adult (>18 years old) | Both | Normal | | details | Feces | Detected and Quantified | 6.661 +/- 7.312 nmol/g wet feces | Adult (>18 years old) | Both | Normal | | details | Feces | Detected and Quantified | 0.753 (0.167-3.540) nmol/g wet feces | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Not Specified | Not Specified | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Not Specified | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 1.1 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 57.701 +/- 18.398 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 1679.674 uM | Adolescent (13-18 years old) | Male | Mitochondrial complex I deficiency due to ACAD9 deficiency | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Autosomal dominant polycystic kidney disease (ADPKD) | | details | Urine | Detected and Quantified | 53.022 +/- 27.201 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Eosinophilic esophagitis | | details | Urine | Detected and Quantified | 0.15 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Gastroesophageal reflux disease | | details |
|
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Mitochondrial complex I deficiency due to ACAD9 deficiency |
---|
- He M, Rutledge SL, Kelly DR, Palmer CA, Murdoch G, Majumder N, Nicholls RD, Pei Z, Watkins PA, Vockley J: A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency. Am J Hum Genet. 2007 Jul;81(1):87-103. Epub 2007 Jun 4. [PubMed:17564966 ]
| Colorectal cancer |
---|
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| Autosomal dominant polycystic kidney disease |
---|
- Gronwald W, Klein MS, Zeltner R, Schulze BD, Reinhold SW, Deutschmann M, Immervoll AK, Boger CA, Banas B, Eckardt KU, Oefner PJ: Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int. 2011 Jun;79(11):1244-53. doi: 10.1038/ki.2011.30. Epub 2011 Mar 9. [PubMed:21389975 ]
| Eosinophilic esophagitis |
---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
|
|
---|
Associated OMIM IDs | - 611126 (Mitochondrial complex I deficiency due to ACAD9 deficiency)
- 114500 (Colorectal cancer)
- 601313 (Autosomal dominant polycystic kidney disease)
- 610247 (Eosinophilic esophagitis)
|
---|
External Links |
---|
DrugBank ID | DB00936 |
---|
Phenol Explorer Compound ID | 428 |
---|
FooDB ID | FDB000882 |
---|
KNApSAcK ID | C00000206 |
---|
Chemspider ID | 331 |
---|
KEGG Compound ID | C00805 |
---|
BioCyc ID | CPD-110 |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Salicylic_Acid |
---|
METLIN ID | 616 |
---|
PubChem Compound | 338 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 16914 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | rw1097271 |
---|
References |
---|
Synthesis Reference | Yin, Yingwu; Guo, Qingbin. Preparation of salicylic acid from phenol. Faming Zhuanli Shenqing Gongkai Shuomingshu (2005), 7pp. |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5. [PubMed:5284360 ]
- Rutner M, Fitzek J, Jahnel-Kracht H, Otto J, Krause W: [Therapy of rheumatic disease with a hydroxyethylsalicylate gel. Results of 2 clinical studies of effectiveness and bioavailability]. Fortschr Med. 1995 Mar 20;113(8):111-3. [PubMed:7759034 ]
- Khan AZ, Aarons L: A note on the use of salicylate saliva concentration in clinical pharmacokinetic studies. J Pharm Pharmacol. 1989 Oct;41(10):710-1. [PubMed:2575150 ]
- Vila MM, Tubino M, de Oliveira Neto G: Determination of salicylate in blood serum by flow injection with immobilized salicylate hydroxylase. J AOAC Int. 2001 Sep-Oct;84(5):1363-9. [PubMed:11601455 ]
- Zaugg S, Zhang X, Sweedler J, Thormann W: Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection. J Chromatogr B Biomed Sci Appl. 2001 Mar 5;752(1):17-31. [PubMed:11254191 ]
- Berkovitch M, Uziel Y, Greenberg R, Chen-Levy Z, Arcusin M, Marcus O, Pinto O, Evans S, Matias A, Lahat E: False-high blood salicylate levels in neonates with hyperbilirubinemia. Ther Drug Monit. 2000 Dec;22(6):757-61. [PubMed:11128247 ]
- Goussis OS, Theodoropoulos TJ: Dilantin and salicylate effects on hepatic thyroxine bio-availability and dialyzable thyroxine. Horm Metab Res. 1990 Jun;22(6):342-4. [PubMed:2379917 ]
- Benfeldt E, Serup J, Menne T: Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. Acta Derm Venereol. 1999 Sep;79(5):338-42. [PubMed:10494706 ]
- Ndovi TT, Choi L, Caffo B, Parsons T, Baker S, Zhao M, Rohde C, Hendrix CW: Quantitative assessment of seminal vesicle and prostate drug concentrations by use of a noninvasive method. Clin Pharmacol Ther. 2006 Aug;80(2):146-58. [PubMed:16890576 ]
- Kocoshis SA, Wong CT: Sodium salicylate and bile acid-induced colonic secretion in the rat. Ann Clin Lab Sci. 1991 May-Jun;21(3):197-204. [PubMed:2064304 ]
- Owen SG, Francis HW, Roberts MS: Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br J Clin Pharmacol. 1994 Oct;38(4):349-55. [PubMed:7833225 ]
- Quaranta A, Portalatini P, Camporeale M, Sallustio V: Effects of salicylates on evoked otoacoustic emissions and remote masking in humans. Audiology. 1999 May-Jun;38(3):174-9. [PubMed:10437688 ]
- Yoshida NH, Roberts MS: Prediction of cathodal iontophoretic transport of various anions across excised skin from different vehicles using conductivity measurements. J Pharm Pharmacol. 1995 Nov;47(11):883-90. [PubMed:8708980 ]
- Alanko K, Stubb S, Salo OP, Reitamo S: Suction blister fluid histamine in fixed drug eruption. Acta Derm Venereol. 1992;72(2):89-91. [PubMed:1350413 ]
- Singh P, Anliker M, Smith GA, Zavortink D, Maibach HI: Transdermal iontophoresis and solute penetration across excised human skin. J Pharm Sci. 1995 Nov;84(11):1342-6. [PubMed:8587053 ]
- Hazouard E, Grimbert M, Jonville-Berra AP, De Toffol MC, Legras A: [Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid]. J Fr Ophtalmol. 1999 Feb;22(1):73-5. [PubMed:10221197 ]
- Schmook FP, Meingassner JG, Billich A: Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm. 2001 Mar 14;215(1-2):51-6. [PubMed:11250091 ]
- Pirola R, Bareggi SR, De Benedittis G: Determination of acetylsalicylic acid and salicylic acid in skin and plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998 Feb 13;705(2):309-15. [PubMed:9521569 ]
- Kunkel A, Watzig H: Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). Arch Pharm (Weinheim). 1999 May;332(5):175-8. [PubMed:10366903 ]
- Azaroual, Imbenotte M, Cartigny B, Lhermitte M, Vermeersch G: [Identification and quantification of exogenous metabolites in biological liquids with new development in NMR spectroscopy in one and two dimensions]. Acta Clin Belg. 1999;53 Suppl 1:97-100. [PubMed:10216993 ]
- Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine RJ: Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J. 1992 Feb 15;282 ( Pt 1):197-202. [PubMed:1540135 ]
- Flower R, Gryglewski R, Herbaczynska-Cedro K, Vane JR: Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol. 1972 Jul 26;238(82):104-6. [PubMed:4505422 ]
- Lonsane BK, Barua PK, Singh HD, Mathur RK, Baruah JN, Iyengar MS: Formation of salicylic acid from naphthalene by microorganisms: Part I. Studies on isolation, characterization & growth of bacterial isolates utilizing naphthalene. Indian J Exp Biol. 1974 Mar;12(2):158-61. [PubMed:4215747 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
---|